Ching Ho Chang

TaiAn Technologies Corp. operates as a technology advisory company. It specializes in commercializing intellectual properties in the life sciences. The firm identifies and transfers promising technologies from the portfolio companies of the fund into Taiwan and to help catapult the local healthcare related industries up to the global competitive levels. The company was founded in February 2002 and is headquartered in Taipei, Taiwan.

Part of United Biomedical, Inc., United Biomedical, Inc. Asia is a private company based in Taipei, Taiwan that specializes in the research, development, manufacturing, and sales of innovative biotech medical products, particularly vaccines based on synthetic peptides for humans and animals. The Taiwanese company utilizes the core technology of its parent company, UBI, called "UBITh® functional antigenicology," to develop these innovative vaccines. The company offers a range of products, including an anti-IL-6 human vaccine and a COVID-19 vaccine called UB-612.

United BioPharma, Inc. engages in the development, manufacture, and sale of monoclonal antibody drug. The company's business activities include the manufacture and sale of western drugs. Its products include trastumab, adalimumab, bevacizumab, rituximab, and omalizumab. The company was founded by Chang Yi Wang on September 30, 2013 and is headquartered in Hsinchu, Taiwan.